Advances in medicine and biology. Volume 108 / Leon V. Berhardt, editor.
Material type:![Text](/opac-tmpl/lib/famfamfam/BK.png)
- text
- computer
- online resource
- 9781536101492
- 1536101494
- 616 23
- R850
Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
![]() |
OPJGU Sonepat- Campus | E-Books EBSCO | Available |
Preface; Hyperpigmentation: Etiology, Topical Treatments and Effectiveness; Abstract; Introduction; Melanogenesis: Physiologic Aspect; Causes of Hyperpigmentation; Epidermal Melanocytosis; Epidermal Pigmented Lesions; Freckles, Lentigines and Solar Lentigo; Epidermal Acquired Pigmented Disorders; Melasma; Acanthosis Nigricans; Dermal Melanocytosis; Dermal Pigmented Lesions; Nevus of Ota and Nevus of Ito; Hori nevus; Dermal Acquired Pigmented Dermatoses; Periorbital Hyperpigmentation; Erythema Dyschromicum Perstans; Riehl Melanosis; Erythromelanosis Follicularis Faciei.
Poikiloderma of CivatteInherited Pigmented Disorders; Familial Lentiginosis Syndrome; Peutz-Jeghers Syndrome; Carney Complex; LEOPARD Syndrome; PTEN Hamartoma Tumor Syndromes; Benign Acquired Lentiginosis; Laugier-Hunziker Syndrome; Post-Inflammatory Hyperpigmentation; Drug and Chemical-Induced Hyperpigmentation; Endocrine and Metabolic Disorders; Addison's Disease; Hemochromatosis; Miscellaneous; Treatment of Skin Hyperpigmentation; Depigmenting Therapies with Lightening Topical Agents; Physical Treatments; Novel Terapeutical Proposal; References; Ankylosing Spondylitis: A Review; Abstract.
1. Introduction2. Ankylosing Spondylitis; 2.1. Aetiology and Incidence; 2.2. Pathophysiology; 2.3. Diagnosis; 2.3.1. Symptoms; 2.3.2. Laboratory Tests; 2.3.3. Imaging; 2.4. Management of the Disease; Surgery; Pharmacological Treatment; Non-Steroidal Anti-Inflammatory Drugs; Anti-Tumour Necrosis Factor (TNF); Non-Pharmacological Therapy; Physical Therapy; Education; Conclusion; References; Pulmonary and Cutaneous CO2 Emission Monitoring under Anesthesia; Patients' Induced Pluripotent Stem Cells to Model Thiopurine Induced Pancreatitis.
Prediction of Thiopurine-Induced Pancreatitis: A Possible Application of Patients' Induced Pluripotent Stem CellsPersonalized Medicine as a Tool to Tailor Therapy and to Prevent Adverse Thiopurine Reactions; Adverse Drug Reactions and Drug-Induced Pancreatitis; Thiopurines in the Treatment of IBD and Manifestation of Adverse Drug Reactions as Pancreatitis; Genetic Markers for Thiopurine-Induced Pancreatitis in Inflammatory Bowel Disease Patients; Induced Pluripotent Stem Cells (iPSC): A Ground-Breaking Tool for Personalized Medicine.
Exocrine Pancreatic Cells from Patients' iPSC as Most Appropriate Cell Subtype to Model TIPThe Molecular Mechanism of TIP Investigated Using Patient Specific iPSC Derived Exocrine Pancreatic Cells; Biotransformation Hypothesis; Innate Immunity Hypothesis; Adaptive Immunity Hypothesis; Caveats of Exocrine Pancreatic Cells Derived from Patients' iPSC as a Model for TIP; The Prevention of TIP Using Patients' iPSC; Conclusion; Acknowledgments; Conflict of Interest; References; Bioluminescence Microscopy in Live Cells: Consideration of Experimental Factors and Practical Recommendations.
Online resource; title from PDF title page (EBSCO, viewed March 2, 2017).
Includes bibliographical references and index.
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide
There are no comments on this title.